Wohlfarth, E.; Kresken, M.; Deuchert, F.; Gatermann, S.G.; Pfeifer, Y.; Pfennigwerth, N.; Seifert, H.; Higgins, P.G.; Werner, G.; Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy.
In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17. Antibiotics 2023, 12, 864.
https://doi.org/10.3390/antibiotics12050864
AMA Style
Wohlfarth E, Kresken M, Deuchert F, Gatermann SG, Pfeifer Y, Pfennigwerth N, Seifert H, Higgins PG, Werner G, Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy.
In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17. Antibiotics. 2023; 12(5):864.
https://doi.org/10.3390/antibiotics12050864
Chicago/Turabian Style
Wohlfarth, Esther, Michael Kresken, Fabian Deuchert, Sören G. Gatermann, Yvonne Pfeifer, Niels Pfennigwerth, Harald Seifert, Paul G. Higgins, Guido Werner, and Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy.
2023. "In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17" Antibiotics 12, no. 5: 864.
https://doi.org/10.3390/antibiotics12050864
APA Style
Wohlfarth, E., Kresken, M., Deuchert, F., Gatermann, S. G., Pfeifer, Y., Pfennigwerth, N., Seifert, H., Higgins, P. G., Werner, G., & Study Group ‘Antimicrobial Resistance‘ of the Paul Ehrlich Society for Infection Therapy.
(2023). In Vitro Activity of Cefiderocol against Clinical Gram-Negative Isolates Originating from Germany in 2016/17. Antibiotics, 12(5), 864.
https://doi.org/10.3390/antibiotics12050864
